Stoke Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 3, 2026, disclosing condensed consolidated financial statements and updated share counts.

Key Highlights

  • Total assets of $406,692 thousand as of September 30, 2026, down from $418,434 thousand as of December 31, 2025, according to the filing.
  • Cash and cash equivalents of $107,271 thousand as of September 30, 2026, compared to $84,220 thousand at December 31, 2025.
  • Marketable securities (current and long-term combined) totaled $251,518 thousand as of September 30, 2026, comprised of $211,916 thousand current and $39,602 thousand long-term.
  • Total liabilities decreased to $54,104 thousand from $65,977 thousand at December 31, 2025, the filing states.
  • Shares outstanding rose to 64,813,537 as of September 30, 2026, from 58,921,999 at December 31, 2025; as of October 30, 2026, shares outstanding were reported as 65,406,268.
  • Additional paid-in capital increased to $1,036,612 thousand from $849,624 thousand at December 31, 2025.
  • Deferred revenue (current and long-term) totaled $10,810 thousand as of September 30, 2026, compared to $18,862 thousand at December 31, 2025.

Stoke Therapeutics' Financial Position as of September 30, 2026

According to the filing, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported total current assets of $354,417 thousand as of September 30, 2026, up from $305,700 thousand at December 31, 2025. The increase in current assets was driven in part by higher cash and cash equivalents and prepaid expenses, which grew from $8,736 thousand to $17,596 thousand over the same period. Accounts receivable also increased to $8,543 thousand from $5,936 thousand at December 31, 2025.

The company disclosed total liabilities of $54,104 thousand as of September 30, 2026, a reduction from $65,977 thousand at year-end 2025. Current liabilities fell to $48,977 thousand from $57,875 thousand, with accrued and other current liabilities declining to $38,584 thousand from $41,035 thousand. Deferred revenue, both current and long-term, also decreased materially over the nine-month period, the filing shows. Long-term marketable securities fell to $39,602 thousand from $106,260 thousand, while operating lease right-of-use assets declined to $1,233 thousand from $3,101 thousand. Property and equipment, net, increased to $8,213 thousand from $3,146 thousand.

The company's stockholders' equity section reflects common stock authorized at 300,000,000 shares with a par value of $0.0001 per share. Additional paid-in capital grew by approximately $186,988 thousand between December 31, 2025 and September 30, 2026, consistent with the increase in shares issued and outstanding over the same period, the filing reports. Restricted cash (long-term) also rose from $227 thousand to $3,227 thousand. The filing notes that it contains forward-looking statements subject to the company's cautionary language and that actual results may differ materially.

What Was Disclosed

Stoke Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data, changes in shares outstanding, and updates to deferred revenue, liabilities, and stockholders' equity relative to December 31, 2025.